Formation of polyglutamine inclusions in non-CNS tissue

被引:222
作者
Sathasivam, K
Hobbs, C
Turmaine, M
Mangiarini, L
Mahal, A
Bertaux, F
Wanker, EE
Doherty, P
Davies, SW
Bates, GP
机构
[1] Kings Coll London, Guys Hosp, GKT Med & Dent Sch, London SE1 9RT, England
[2] Univ London Univ Coll, Dept Anat & Dev Biol, London WC1E 6BT, England
[3] Max Planck Inst Mol Genet, Berlin, Germany
基金
英国惠康基金;
关键词
D O I
10.1093/hmg/8.5.813
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Huntington's disease (HD) is one of a class of inherited progressive neurodegenerative disorders that are caused by a CAG/polyglutamine repeat expansion, We have previously generated mice that are transgenic for exon 1 of the HD gene carrying highly expanded CAG repeats which develop a progressive movement disorder and weight loss with similarities to HD. Neuronal inclusions composed of the exon 1 protein and ubiquitin are present in specific brain regions prior to onset of the phenotype, which in turn occurs long before specific neurodegeneration can be detected. In this report we have extended the search for polyglutamine inclusions to non-neuronal tissues, Outside the central nervous system (CNS), inclusions were identified in a variety of post-mitotic cells. This is consistent with a concentration-dependent nucleation and aggregation model of inclusion formation and indicates that brain-specific factors are not necessary for this process. To possibly gain insights into the wasting that is observed in the human disease, we have conducted a detailed analysis of the timing and progression of inclusion formation in skeletal muscle and an investigation into the cause of the severe muscle atrophy that occurs in the mouse model. The formation of inclusions in non-CNS tissues will be particularly useful with respect to in vivo monitoring of pharmaceutical agents selected for their ability to prevent polyglutamine aggregation in vitro, without the requirement that the agent can cross the blood-brain barrier in the first instance.
引用
收藏
页码:813 / 822
页数:10
相关论文
共 49 条
[1]  
Askanas V, 1998, SCAND J RHEUMATOL, V27, P389
[2]  
ASKANAS V, 1997, ACTA MYOL, V1, P21
[3]  
Bancroft J. D., 1990, THEORY PRACTICE HIST
[4]   Transgenic mice in the study of polyglutamine repeat expansion diseases [J].
Bates, GP ;
Mangiarini, L ;
Davies, SW .
BRAIN PATHOLOGY, 1998, 8 (04) :699-714
[5]   Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length [J].
Becher, MW ;
Kotzuk, JA ;
Sharp, AH ;
Davies, SW ;
Bates, GP ;
Price, DL ;
Ross, CA .
NEUROBIOLOGY OF DISEASE, 1998, 4 (06) :387-397
[6]  
BOLT JMW, 1973, Q J MED, V42, P151
[7]  
BOURFINKELAN I, 1998, NEUROREPORT, V9, P1823
[8]   Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy [J].
Brais, B ;
Bouchard, JP ;
Xie, YG ;
Rochefort, DL ;
Chrétien, N ;
Tomé, FMS ;
Lafrenière, RG ;
Rommens, JM ;
Uyama, E ;
Nohira, O ;
Blumen, S ;
Korcyn, AD ;
Heutink, P ;
Mathieu, J ;
Duranceau, A ;
Codère, F ;
Fardeau, M ;
Rouleau, GA .
NATURE GENETICS, 1998, 18 (02) :164-167
[9]  
CARTER RJ, 1999, IN PRESS J NEUROSCI
[10]   Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene [J].
Cha, JHJ ;
Kosinski, CM ;
Kerner, JA ;
Alsdorf, SA ;
Mangiarini, L ;
Davies, SW ;
Penney, JB ;
Bates, GP ;
Young, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6480-6485